BIOSECURE Act drives CRO and CDMO reshoring for biopharma

Modern Catalyst

The BIOSECURE Act represents a structural inflection point for clinical outsourcing strategy in 2025–2026. Unlike earlier supply-chain diversification efforts, which were largely voluntary and cost-driven, BIOSECURE imposes mandatory vendor governance and de-risking timelines on any biopharma organization conducting federally funded or regulated research. The law does not operate through a static blacklist; instead, designation process evolves through OMB framework incorporating existing national-security authorities and future interagency determinations. This dynamic approach means procurement teams cannot simply audit a vendor once and move on—compliance becomes an ongoing operational requirement.

The clinical trial landscape itself is shifting in parallel. U.S. is losing trial volume to Australia and China, driven by cost pressures, regulatory complexity, and site availability. Yet BIOSECURE creates a countervailing force: companies that can demonstrate U.S.-domiciled or trusted-ally CRO partnerships gain competitive advantage in regulatory review, investor confidence, and supply-chain resilience. Eli Lilly's $27 billion U.S. manufacturing commitment signals that large-cap pharma is treating BIOSECURE compliance not as a checkbox but as a strategic asset. For smaller biotech firms, however, the calculus is harsher. Small biotech with single clinical-stage asset faces 12–18 months delays and millions in additional costs during a period of capital scarcity—a dynamic that will accelerate consolidation and push mid-tier CROs into higher demand.

Structural Impact

BIOSECURE reshapes three critical dimensions of CRO vendor selection: governance visibility, geographic footprint, and operational resilience.

Governance and third-party transparency are now non-negotiable. Organizations need greater visibility into third parties and stronger governance over outsourced research operations. This means procurement teams must implement due-diligence frameworks that go beyond traditional cost and timeline metrics. A CRO's subcontractor network—including data analytics providers, laboratory suppliers, and IT infrastructure partners—must be auditable and compliant. CDMO selection scorecards and KPIs updated April 2026 with BIOSECURE Act impacts now include vendor-of-vendor risk assessment, geopolitical exposure scoring, and attestation workflows. Organizations that lack this infrastructure will face contract renegotiation, audit delays, and potential regulatory pushback during IND or BLA review.

Geographic concentration and reshoring are accelerating. The clinical outsourcing market has historically favored low-cost jurisdictions (India, China) for data management, biostatistics, and site coordination. BIOSECURE does not ban these services outright, but it creates compliance friction and reputational risk that makes U.S. and EU-based CROs more attractive to risk-averse sponsors. WuXi AppTec involved in production of about a quarter of drugs used in U.S., with U.S. market accounting for roughly 69% of 2025 revenue, illustrates both the scale of current offshore dependency and the urgency of reshoring. Capacity constraints in trusted-ally CROs (U.S., Canada, EU, UK, Australia, Japan) will tighten in 2025–2026, pushing procurement teams to negotiate longer timelines and premium pricing for compliant vendors.

Operational resilience and dual-sourcing become mandatory for Phase II and Phase III programs. A single CRO dependency—even a large, reputable one—now carries geopolitical and regulatory risk. Procurement teams are increasingly adopting a "trusted-ally cluster" model: primary CRO in the U.S., secondary data-management partner in Canada or EU, biostatistics support in Australia or UK. This redundancy increases direct costs but reduces the risk of program delay if a vendor faces BIOSECURE designation or supply-chain disruption. Industries relying on outsourced research capabilities include pharmaceutical and biologics developers, CROs, and specialized laboratory providers now face heightened scrutiny from both sponsors and regulators.

Strategic Blueprint

For procurement leaders navigating BIOSECURE-era CRO selection, four priorities emerge:

1. Audit vendor supply chains now, not at contract signature. Before issuing an RFP, conduct a preliminary geopolitical risk assessment of your shortlist. Request vendor attestations on subcontractor location, data residency, and any ties to designated entities. Ask for evidence of BIOSECURE compliance readiness—not a checkbox, but a documented governance process. Vendors that cannot articulate their third-party risk management framework should be deprioritized, regardless of cost savings.

2. Embed compliance into scorecard weighting. Traditional CRO selection emphasizes cost (30–40%), timeline (20–30%), and quality/experience (20–30%). In 2025–2026, add a compliance and resilience category weighted at 15–25%. This should include: (a) geographic footprint diversity; (b) data residency and encryption standards; (c) vendor-of-vendor audit frequency; (d) attestation of no ties to BIOSECURE-designated entities; (e) redundancy and failover protocols. A vendor with 10% cost advantage but single-geography data management should score lower than a higher-cost, multi-jurisdiction partner.

3. Negotiate longer timelines and premium pricing as a hedge. BIOSECURE-compliant CROs will command pricing premiums of 5–15% in 2025–2026 as capacity tightens. Rather than resist this, build it into your budget and timeline assumptions. A 12-month Phase IIb program may now require 14–16 months if you insist on dual-sourcing and full vendor audits. Sponsors that plan for this reality will avoid last-minute crisis contracting and regulatory delays.

4. Establish a vendor governance cadence. BIOSECURE compliance is not a one-time audit. Implement quarterly or semi-annual vendor reviews that include: (a) updates to subcontractor roster; (b) any changes in ownership or control; (c) new data-residency or encryption policies; (d) attestation renewals. Larger sponsors should consider appointing a dedicated supply-chain compliance officer to manage this workflow across all CRO and CDMO partnerships.

5. Plan for consolidation and capacity constraints. Top-20 pharma companies have already begun diversification planning, treating BIOSECURE as one element of broader China de-risking strategies. Mid-tier and smaller CROs will consolidate or be acquired by larger, BIOSECURE-ready platforms. Procurement teams should map their vendor landscape for the next 24–36 months: which CROs are likely acquisition targets? Which have the capital to invest in U.S. capacity? Which are at risk of BIOSECURE designation or geopolitical pressure? Early visibility into these dynamics will help you lock in favorable terms before capacity fully tightens.

BIOSECURE Act drives CRO and CDMO reshoring for biopharma

Modern Catalyst

Structural Impact

Strategic Blueprint

Sources